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Objectives. This study sought to 1) determine the effect of
gender on early and late infarct-related artery patency and
reocclusion after thrombolytic therapy for acute myocardial in-
farction; 2) examine the effect of gender on left ventricular
function in response to injury/reperfusion; and 3) assess the
independent contribution of gender to early (30-day) mortality
after acute myocardial infarction.
Background.Women have a higher mortality rate than men after
myocardial infarction. However, the effect of gender on infarct-related
coronary artery patency and left ventricular response to injury/
reperfusion have not been fully defined in the thrombolytic era.
Methods. Patency rates and global and regional left ventricular
function were determined in patients at 90 min and 5 to 7 days
after thrombolytic therapy for acute myocardial infarction. The
effect of gender on infarct-related artery patency and left ventric-
ular function was determined. Thirty-day mortality differences
between women and men were compared.
Results. Women were significantly older and had more hyperten-
sion, diabetes, hypercholesterolemia, heart failure and shock. They
were less likely to have had a previous myocardial infarction, history
of smoking or previous bypass surgery. Ninety-minute patency rates
(Thrombolysis in Myocardial Infarction [TIMI] flow grade 3) in
women and men were 39% and 38%, respectively (p 5 0.5). Reocclu-
sion rates were 8.7% in women versus 5.1% in men (p 5 0.14).
Women had more recurrent ischemia than men (21.4% vs. 17.0%,
respectively, p 5 0.01). Ninety-minute ejection fraction and regional
ventricular function were clinically similar in women and men with
TIMI 2 or 3 flow (ejection fraction [mean 6 SD]: 63.4 6 6% vs.
59.4 6 0.7%, p 5 0.02; number of chords: 21.4 6 0.9 vs. 21.0 6 1.9,
p 5 0.7; SD/chord: 22.4 6 08 vs. 22.4 6 0.2, p 5 0.9, respectively).
No clinically significant differences in left ventricular function were
noted at 5- to 7-day follow-up. Women had a greater hyperkinetic
response than men in the noninfarct zone (SD/chord: 2.4 6 0.2 vs.
1.76 0.1, p5 0.005). The 30-day mortality rate was 13.1% in women
versus 4.8% in men (p <2 0.0001). After adjustment for other clinical
and angiographic variables, gender remained an independent deter-
minant of 30-day mortality.
Conclusions. Women do not differ significantly from men with
regard to either early infarct-related artery patency rates or
reocclusion after thrombolytic therapy or ventricular functional
response to injury/reperfusion. Gender was an independent deter-
minant of 30-day mortality after acute myocardial infarction.
(J Am Coll Cardiol 1997;29:35–42)
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The incidence of coronary artery disease in women increases
after menopause, equaling that of men by the age of 70 (1). It
is the leading cause of mortality in older women, accounting
for one-third of all deaths. The mortality rate of women in the
setting of acute myocardial infarction is generally regarded as
higher than that in men (2–6), and this difference continues to
exist in the era of reperfusion therapy despite an equivalent
decrease in mortality in both men and women (7–11). Most of
the excess mortality has been accounted for by increased rates
of comorbidities, such as hypertension (12), advanced age
(5,13) and diabetes mellitus (4,12,14). There is evidence of
decreased rates of catheterization and angioplasty (14–16) and
underutilization of thrombolytic agents (17,18) in women,
possibly due to fears of increased risk of complications or to
selection bias (12,19–25), factors that may contribute to the
greater mortality noted in women.
Other potential explanations for the worse outcome in
women include higher rates of failed thrombolysis, increased
incidence of reocclusion and reinfarction and accentuated
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myocardial injury in response to ischemia and reperfusion. The
effect of gender on the rate of successful thrombolysis and
ventricular response to injury and reperfusion has not been
well studied.
Analysis of the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Arteries
(GUSTO-I) trial (26) found gender to be an independent
predictor of 30-day mortality, after adjustment for clinical
variables (27). In a separate analysis, the mortality benefit of
thrombolytic therapy was equivalent in men and women,
despite a higher stroke rate in women (28). The GUSTO-I
Angiographic Study (29) offered a unique opportunity to assess
the effect of gender on infarct-related artery patency after
thrombolytic therapy and the effect of gender on left ventric-
ular response to ischemia/reperfusion. In addition, the inde-
pendent effect of gender on short-term (30-day) mortality
could be determined after adjustment for both clinical and
angiographic variables.
Methods
Study patients. The GUSTO-I Angiographic Study has
been described in detail previously (29). Briefly, patients were
included in the GUSTO-I trial if they had chest pain ,6 h in
duration and ST segment elevation in at least two contiguous
electrocardiographic leads. We compared global and regional
left ventricular function after thrombolysis in men and women
who had angiographically documented patency (Thrombolysis
in Myocardial Infarction [TIMI] flow grade 2 and 3) in the
infarct-related coronary artery 90 min (645 min) after throm-
bolytic therapy, sustained patency at 5- to 7-day follow-up
angiography and ventriculograms adequate for analysis. We
also compared noninfarct zone function at 90 min in all male
and female patients randomized to 90-min angiography with
adequate ventriculograms for analysis regardless of 90-min
TIMI flow grade.
Thrombolytic therapy and coronary angiography. As de-
scribed previously (26), patients were randomized to one of
four thrombolytic regimens. At the time of drug randomiza-
tion, patients were also randomized to one of four times for
initial coronary angiography after the start of thrombolytic
therapy. This report includes angiographic data only from
those patients randomized to 90-min postthrombolytic therapy
angiography. These patients also had 5- to 7-day follow-up
catheterization.
Core angiographic laboratory procedures and cineangio-
graphic analysis. Films were interpreted by an experienced
angiographer (C.F.L., J.S.R., A.M.R.) who had no knowledge
of treatment allocation, angiographic randomization or gen-
der. Infarct-related artery patency as defined by TIMI flow
grade was assessed according to standard methods (30). Ven-
triculographic silhouettes were acquired digitally at end-systole
and end-diastole, and the borders were defined by the core
laboratory angiographer. Ventricular volumes and ejection
fraction were calculated by the single plane area-length
method (31). Regional ventricular function was assessed by the
method of Bolson et al. (32) and included mean excursion of
the most abnormal 50% of chords in the infarct region,
expressed as the number of standard deviations per chord
(SD/chord) and the number of consecutive chords in the
infarct region more than two standard deviations below
the norm. The noninfarct region was similarly assessed as the
SD/chord of the most normal 50% of chords. Patients who
underwent coronary angioplasty were excluded from analysis
of ventricular function.
Rescue angioplasty definition. Patients with TIMI flow
grade 0 or 1 in the infarct-related artery at the time of 90-min
catheterization or who had reocclusion of an initially patent
(TIMI flow grade 2 or 3) infarct-related artery and underwent
immediate attempted angioplasty with cine films adequate for
analysis were classified as having undergone rescue angioplasty
attempts. Successful rescue angioplasty was defined as conver-
sion from TIMI flow grade 0 or 1 to TIMI flow grade 2 or 3 and
,50% residual stenosis at the completion of the angioplasty
procedure.
Statistical analysis. Results are expressed as mean value6
SEM, unless otherwise noted. Chi-square analysis was utilized
to compare categoric data, and continuous variables were
compared using the unpaired Student t test (two-tailed).
Multivariable linear regression analysis (33) was utilized to
determine the independent effect of clinical and angiographic
variables in the prediction of regional and global left ventric-
ular function indexes. The effect of gender on mortality was
analyzed by multivariable logistic regression analysis (33).
Demographic and angiographic variables that were considered
possibly related to left ventricular functional outcomes or
mortality, or both, were incorporated into the models, and the
independent effect of each variable was determined. Clinical
variables for testing were chosen on the basis of their previ-
ously described independent effect on 30-day mortality (27)
and included gender, age, diabetes, previous history of infarc-
tion and initial heart rate and systolic blood pressure. Angio-
graphic variables included 90-min (645) TIMI flow grade and
multivessel coronary artery disease. The TIMI flow grade was
entered as a dichotomous variable (TIMI flow grade 0, 1 and
2 vs. TIMI flow grade 3) to reflect its biologic significance (29).
Continuous variables were entered into the model without
modification except where indicated. Adjusted relative odds
ratios were also determined with 95% confidence intervals. A
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
GUSTO 5 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries trial
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
SD/chord 5 standard deviations per chord
TIMI 5 Thrombolysis in Myocardial Infarction
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p , 0.05 was considered indicative of statistical significance in
all cases.
The difference in 30-day survival between women and men
was determined by Kaplan-Meier curves. The significance of
the difference was determined by the log rank test.
Results
Patient characteristics. The GUSTO-I Angiographic
Study enrolled 2,431 patients (543 women, [22.3%], 1,887 men
[77.7%]). The gender of one patient was not documented.
Women differed from men in many baseline variables (Table
1): They were older (66.2 6 11.2 vs. 59.0 6 11.5, p # 0.01) and
more often had a history of hypertension, diabetes and hyper-
cholesterolemia. Women were also more likely to be treated
later than men (mean time from symptom onset to initiation of
thrombolytic therapy 3.3 6 1.4 vs. 3.0 6 1.5 h, p 5 0.003).
Although women had a similar incidence of multivessel coro-
nary artery disease at the time of enrollment in the trial, the
incidence of previous coronary artery bypass graft surgery
(CABG) was more than twofold less than that in men (5.1% vs.
2%, p5 0.002). Also, despite a similar incidence of multivessel
coronary artery disease and anterior infarction, women were
twice as likely to have congestive heart failure or cardiogenic
shock during the course of their hospital stay than men.
Although women were significantly more likely to have recur-
rent ischemia during their hospital stay, there was no signifi-
cant difference between genders with regard to reinfarction
(Table 2).
Thrombolytic regimen randomization. A similar propor-
tion of women and men were randomized to each thrombolytic
regimen: recombinant tissue-type plasminogen activator plus
intravenous heparin 29.1% versus 31.3%; streptokinase
plus intravenous heparin 24.2% versus 21.0%; streptokinase
plus subcutaneous heparin 15.2% versus 20.5%; and combina-
tion therapy 31.5% versus 31.3% (all p . 0.05).
Effect of gender on 90-min patency, reocclusion and collat-
eral circulation. Ninety-minutes after thrombolytic therapy,
no significant difference was noted with regard to infarct-
related artery patency (TIMI flow grade 2 and 3) rates in
women versus men (69.0% versus 66.5%, respectively, p 5
0.46). This sample size of women and men is sufficient to detect
a 10 percentage point decrease in patency (TIMI 2 and 3 flow
grades) in women compared with men with a power of 80%, or
a 20 percentage point difference with .99% power. Also of
note, there was an equal proportion of women and men with
fully normal (TIMI flow grade 3) flow 90-min after thrombo-
lytic therapy (Table 3). The power to detect a 10 percentage
point difference in 90-min TIMI flow grade 3 between women
and men with this sample size is 83%. Reocclusion of initially
patent (TIMI flow grade 2 and 3) infarct-related arteries was
rare and occurred in 8.7% of female and 5.1% of male patients
(p 5 0.14). The power to detect a 10 or 15 percentage point
difference in reocclusion of initialy patent infarct-related ar-
teries between women and men is 91% and 99.5%, respec-
tively. Angiographically visible collateral vessels were seen in
16.0% of women and 14.1% of men (p 5 0.4).
Follow-up angiography. Of 721 patients (165 women, 556
men) with a patent (TIMI flow grade 2 or 3) infarct-related
artery at 90 min, 1-week follow-up angiography was performed
in 87 (52.7%) of 165 women and 394 (70.8%) of 556 men (p #
0.0001). Among the 240 patients who did not have follow-up
angiography (78 women, 162 men), 18 (23.1%) of 78 women
and 17 (10.5%) of 162 men died before follow-up (odds ratio
[OR] 2.6, 95% confidence interval [CI] 1.2 to 5.3), whereas 60
(76.9%) of 78 women and 145 (89.5%) of 162 men failed to
have follow-up angiography because of patient or physician
Table 1. Baseline Clinical Characteristics of the 2,431 GUSTO-I
Angiographic Study Patients According to Gender
Women Men p Value
Age (yr) 68 (59, 75) 59 (50, 67)
.75 yr 24.0 8.0 , 0.001
Hypertension 50.0 33.0 , 0.001
Diabetes 19.0 11.1 , 0.001
Hypercholesterolemia 38.3 33.3 0.03
Body weight (kg) 67 (59, 77) 80 (72, 90)
History of smoking 52.0 77.0 , 0.001
Previous MI 12.0 14.3 0.15
Previous CABG 2.0 5.1 0.002
Values represent median (25th, 75th percentiles) for continuous variables or
percent of patients in each category. CABG 5 coronary artery bypass graft
surgery; MI 5 myocardial infarction.
Table 2. Outcome of the 2,431 GUSTO-I Angiographic Study
Patients According to Gender
Women Men p Value
Time to treatment (h) 3.0 (2.2, 4.2) 2.75 (2.0, 3.8)
Anterior MI 41.0 37.4 0.20




CHF 25.1 12.3 , 0.001
Shock 10.0 5.2 , 0.001
Reinfarction 5.0 3.7 0.17
Recurrent ischemia 21.4 17.0 0.013
CABG (in hospital) 10.3 9.9 0.75
PTCA (in hospital) 36.0 36.0 0.28
*Single-vessel disease versus multivessel disease. Values represent median
(25th, 75th percentiles) for continuous variables or percent of patients in each
category. CHF 5 congestive heart failure; PTCA 5 percutaneous transluminal
coronary angioplasty; other abbreviations as in Table 1.
] ]
Table 3. Gender and 90-Minute Angiographic Patency (n 5 1,075)*
TIMI Flow Grade
0 or 1 [% (no.)] 2 [% (no.)] 3 [% (no.)]
Women 30.9 (74) 30.5 (73) 38.5 (92)
Men 33.5 (280) 28.7 (240) 37.8 (316)
*p . 0.05 for all comparisons. TIMI 5 Thrombolysis in Myocardial
Infarction.
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refusal, reocclusion, intervening percutaneous transluminal
coronary angioplasty (PTCA) or follow-up angiography that
was performed before the prespecified 5- to 7-day time period.
Procedures and outcomes. Percutaneous transluminal cor-
onary angioplasty was performed in 185 (35.9%) of 515 women
versus 654 (35.8%) of 1,826 men (p5 0.9). Data for PTCA was
not available for 28 women, 61 men and 1 patient of unknown
gender. The overall mortality rate in women undergoing PTCA
was 8.1% (15 of 185) versus 5.2% (34 of 654) in men (p 5
0.14). Cineangiograms were available for core laboratory anal-
ysis from 49 women and 181 men who underwent rescue
PTCA. Rescue PTCA was successful in 43 (87.8%) of 49
women versus 157 (88.7%) of 181 men (p5 0.8). The mortality
rate in women with successful rescue PTCA was 11.6% (5 of
43) versus 7.6% (12 of 157) in men (OR 1.6, 95% CI 0.5 to 4.7).
Coronary artery bypass surgery was performed in 56 (10.3%)
of 542 women and 186 (9.9%) of 1,884 men (p 5 0.75). The
status of five patients (one woman, three men, 1 patient of
unknown gender) with regard to CABG is unknown. The
mortality rate in women with CABG was 10.7% (6 of 56)
versus 3.8% (7 of 186) in men (p 5 0.08).
Effect of gender on left ventricular function. Indexes of
global and regional left ventricular function in men and women
90 min and 5 to 7 days after successful thrombolysis in patients
with ventriculograms adequate for analysis are shown in Table
4. There were no clinically significant differences in either
global or infarct zone regional left ventricular function either
at 90 min or 5- to 7 days after successful thrombolysis in men
compared with women. However, women did have a signifi-
cantly greater degree of hyperkinesia in the noninfarct zone
acutely and at 1 week follow-up than men.
The male and female patient groups were of greatly differ-
ent sizes. The power to detect a difference of eight chords, or
0.6 SD/chord in regional ventricular function, in men com-
pared with women at the 0.05 level of significance with the
number of patients shown in Table 3 for 90-min ventriculog-
raphy is 99% and 75%, respectively. The corresponding powers
to detect similar differences at 5- to 7-day ventriculography
with the number of patients in each group are 97% and 75%,
respectively.
Multivariable analysis: independent determinants of ven-
tricular function. The independent determinants of left ven-
tricular function at 90 min and 5 to 7 days after myocardial
infarction are shown in Table 5. Female gender is a significant
determinant of lower end-systole volume index and noninfarct
zone ventricular function at 90 min but not of ejection fraction.
Female gender is a significant determinant of 5- to 7-day global
left ventricular function (i.e., female gender is associated with
a higher 5- to 7-day ejection fraction and lower end-systolic
volume index than male gender after adjusting for other
variables). However, gender has no effect on regional (infarct
or noninfarct zone) ventricular function 1-week after occlu-
sion/reperfusion of the infarct-related artery.
Mortality. The unadjusted 30-day mortality rate in women
was 13.1% versus 4.8% in men (p , 0.0001) (Fig. 1). Female
patients with a patent infarct-related artery 90-min after
thrombolytic therapy had a mortality rate of 11.5% versus
3.8% in men (OR 3.3, 95% CI 1.7 to 6.3). Women with an
occluded infarct-related artery at 90-min had a mortality rate
of 19.0% versus 5.4% in men (OR 4.1, 95% CI 2.0 to 9.0). The
mortality rate in those with stroke was 38% in women versus
33% in men (p 5 0.75). After adjustment for age, gender
remained a significant independent determinant of 30-day
mortality, as shown in Figure 2 (p 5 0.002). After adjustment
for clinical or angiographic variables, or both, gender remained
an independent predictor of 30-day mortality (Fig. 3).
Discussion
Infarct-related artery patency and reocclusion. The early
postmyocardial infarction mortality rate for women continues
to exceed that of men in the reperfusion era (7–11). However,
our data demonstrate that successful thrombolysis 90 min after
administration of a thrombolytic regimen is achieved in equal
proportions of women and men. Complete normalization of
coronary flow (TIMI flow grade 3) in the infarct-related artery,
Table 4. Indexes of Global and Regional Ventricular Function According to Gender, After Thrombolysis, in Patients With Patent
Infarct-Related Arteries
EF (%) ESVI No. of Chords
SD/Chord
Infarct Zone Noninfarct Zone
90-min ventriculography
Women 63.4 6 1.6* 21.6 6 1.1 21.0 6 1.9† 22.4 6 0.2 2.4 6 0.2§
(n 5 86) (n 5 76) (n 5 85) (n 5 85) (n 5 85)
Men 59.4 6 0.7 28.5 6 0.8 21.4 6 0.9 22.3 6 0.1 1.7 6 0.1
(n 5 367) (n 5 311) (n 5 365) (n 5 365) (n 5 365)
5–7-day ventriculography
Women 63.1 6 1.5\ 23.3 6 1.3¶ 18.0 6 1.9 21.9 6 0.2 1.9 6 0.2#
(n 5 83) (n 5 69) (n 5 80) (n 5 82) (n 5 82)
Men 58.4 6 0.7 29.0 6 0.8 17.0 6 0.9 22.0 6 0.1 1.3 6 0.1
(n 5 359) (n 5 304) (n 5 352) (n 5 356) (n 5 356)
*p 5 0.02. †p 5 0.0001. §p 5 0.005. \p 5 0.004. ¶p 5 0.0002. #p 5 0.008. EF 5 ejection fraction; ESVI 5 end-systolic volume index.
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a finding previously shown (29) to be highly correlated with
convalescent ventricular function and early mortality, also
occurs in equal proportions of women and men. Angiographic
reocclusion of an initially patent infarct-related artery, an
event associated with high mortality (34), occurred more
frequently in women than men, although the difference did not
reach statistical significance. This may be due to the relatively
small sample size of our study or the paucity of reocclusion in
general in the present study. Of note, the main GUSTO-I trial
did show a slight increase in clinical reinfarction in women
compared with men (OR 1.3, 95% CI 1.12 to 1.41) (28). Our
study also demonstrated a similar trend toward increased
reinfarction in women, although it failed to reach statistical
significance.
Women were less likely to have a history of smoking than
men. Several studies, including an analysis from GUSTO-I
(35,36), have suggested that smokers have a higher thrombus
burden at the infarct site and are more likely to respond
favorably to thrombolysis, with higher patency rates and lower
rates of reinfarction and recurrent ischemia. However, it would
appear unlikely that a significant proportion of the excess
mortality in women noted in the present study can be attrib-
uted to failed thrombolysis. Increased rates of reocclusion/rein-
farction may contribute to the increased early mortality noted
in women, although this remains to be definitely determined.
Left ventricular function. We documented that there is no
difference in the infarct zone regional response of the myocar-
dium to injury/reperfusion in women compared with men.
However, women had a slightly greater ejection fraction and a
smaller end-systolic volume index than men 90 min and 5 to 7
Table 5. Multivariate Analysis: Clinical and Angiographic Independent Determinants of Global and Regional Left Ventricular Function After
Acute Myocardial Infarction







SD/Chord (n 5 1,046)
MI Zone Non-MI Zone
Women 0.2 0.0003 0.6 0.3 0.03
Previous MI , 0.0001 , 0.0001 , 0.0001
Anterior MI , 0.0001 , 0.0001 , 0.0001 , 0.0001 , 0.0001
TIMI flow (90 min) , 0.0001 0.0007 , 0.0001 , 0.0001







SD/Chord (n 5 779)
MI Zone Non-MI Zone
Women 0.02 0.02 0.3 0.7 0.24
Previous MI , 0.0001 , 0.0001 , 0.0001
Anterior MI , 0.0001 , 0.0001 , 0.0001 0.05 , 0.0001
TIMI flow (90 min) 0.0003 0.002 , 0.0001 ,0.0001
Data presented are p value for the independent variable. Abbreviations as in Tables 1, 3 and 4.
Figure 1. Kaplan-Meier analysis of the effect of gender on 1-year
survival after myocardial infarction. F 5 female; M 5 men. Upper
curves 5 men; lower curves 5 women. Figure 2. Effect of age on 30-day mortality after myocardial infarction
according to gender. Circles 5 women; triangles 5 men.
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days after successful thrombolysis, a finding that did reach
statistical significance. Despite this finding, women were twice
as likely to develop congestive heart failure and cardiogenic
shock than men. Numerous studies have shown (4–6,12,37,38)
that the incidence of congestive heart failure is higher in
women after myocardial infarction, although the Thrombolysis
and Angioplasty in Myocardial Infarction (TAMI) investiga-
tors (39) found no difference. There is also conflicting data on
the incidence of cardiogenic shock in women in the setting of
acute myocardial infarction (6,12,37). It is possible that the
female population, due to a greater prevalence of hypertension
and diabetes, has a greater degree of diastolic dysfunction,
leading to more congestive heart failure (40,41). Notably, in
our cohort, women had significantly better noninfarct zone
systolic function than men. Because there was no difference in
the prevalence of previous myocardial infarction or multivessel
disease, one potential explanation for this finding is that
women have a different adrenergic response to infarction,
leading to an increased hyperkinesia of the noninfarct zone.
Also, the relative lack of previous CABG procedures in women
despite equivalent rates of previous infarction and multivessel
disease might be expected to adversely affect noninfarct zone
function, thus contributing to the excess in heart failure.
However, this was not found in our study cohort.
In-hospital procedures. Some investigators (14–16) have
reported that women are less likely to be referred for cardiac
catheterization and subsequent revascularization procedures
than men after myocardial infarction. However, in the present
study, women and men were referred for revascularization in
equal proportions. Of note, the success rates of rescue angio-
plasty were equivalent in each gender. There was a trend
toward increased mortality after CABG in women in this study,
although not statistically significant in this cohort. However,
given the small sample size we are unable to state that
differences in outcomes between women and men after CABG
do not account for at least a proportion of the excess early
mortality noted in women in the present study (27).
Mortality. The increased mortality noted in women after
myocardial infarction has been attributed to an excess of
adverse comorbid factors (4,5,12–14). The GUSTO-I trial of
.41,000 patients identified a number of predictors of 30-day
mortality (27). After adjustment for multiple baseline charac-
teristics, female gender was a significant independent prognos-
tic factor for 30-day mortality but only marginally so (27). The
only previous angiographic study to evaluate this group (TAMI
[39]), did not find gender to be a significant independent
determinant of early postinfarction mortality after adjustment
for clinical or angiographic variables, or both, although a trend
was evident. However, our data suggest that the excess early
mortality in women cannot be fully explained by more adverse
clinical characteristics noted in the female population by
adjustment for angiographic variables. Furthermore, our re-
sults suggest that within this trial cohort, there was not a
systematic gender bias in referrals for revascularization thera-
pies, which may effect mortality. It should also be noted that
the confidence limits surrounding the point estimate of 30-day
mortality after adjustment for clinical and angiographic vari-
ables are wide, ranging between 1.2 and 3.7. These data are in
accord with the results of the GUSTO-I main trial in 41,021
patients (27,28); the wide confidence intervals in our study are
due to the relatively smaller sample size.
Our findings suggest, therefore, that the early (30-day)
mortality difference between men and women is due to yet to
be defined variables or to the small but cumulative effects of
numerous variables (e.g., reocclusion differences, post-CABG
mortality), which may not be captured within the confines of
multivariable analysis. However, our data strongly suggest that
neither differences between women and men with regard to
thrombolytic-induced infarct-related artery patency rates nor
differences in the response of the ventricular myocardium to
ischemia/reperfusion contribute significantly to any difference
in a 30-day mortality.
Study limitations. The present study has several limita-
tions inherent to subgroup analysis. The GUSTO-I angio-
graphic trial data base was designed to evaluate the efficacy of
several thrombolytic regimens on early infarct-related artery
patency and left ventricular functional outcomes. Because
patients were not randomized according to gender, the pro-
portion of female and male patients in this study was unequal.
The failure to detect differences in regional left ventricular
function between women and men could thus be due to lack of
sufficient statistical power. However, we provided power cal-
culations for the determination of differences in regional
function that we consider to be clinically significant in relation
to the number of female and male patients included in our
analysis. Similarly, the failure to detect a difference between
women and men with regard to 90-min patency and subsequent
infarct-related artery reocclusion may be limited by our sample
size. However, as we showed, we do have sufficient power to
detect differences that would be considered clinically signifi-
Figure 3. Effect of gender on 30-day mortality after adjustment for
clinical or angiographic variables, or both. The relative ORs (squares)
and 95% CIs (horizontal lines) for mortality are plotted for men versus
women. A ratio .1 denotes higher risk for mortality among women.
Clinical variables included age, diabetes, history of previous myocar-
dial infarction and initial heart rate and blood pressure. Angiographic
variables included multivessel disease and 90-min TIMI flow grade.
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cant. A $10% difference in early patency or reocclusion rates
would be detected with a power of .80% in each instance.
We also provided data on mortality differences (univariable
analyses) between women and men after CABG and PTCA.
These mortality rates should only be considered descriptive of
this particular cohort. Our sample size is too limited to draw
any specific conclusions regarding postprocedural mortality.
Other limitations include the fact that 1-week follow-up
angiography rates differed between women and men. This
difference was largely due to the excess number of female
patient deaths relative to male patient deaths in the first
postinfarction week. The lower rate of angiographic follow-up
may have reduced our ability to detect significant differences in
the male and female ventricular response to injury/reperfusion.
Also, because it was not a requirement of the trial to have all
rescue or elective angioplasty films reviewed in the core
angiographic laboratory, a potential for bias exists in that
particular analysis.
Conclusions. Thrombolytic therapy is equally efficacious in
establishing early patency in the infarct-related artery in
women and men. Reinfarction and reocclusion of an initially
patent infarct-related artery tended to be more common in
female patients but were not statistically significant in our
sample. There is no gender-specific difference between the
female and male myocardium in response to injury/
reperfusion. Hyperkinesia of the noninfarct zone is signifi-
cantly greater in women than men. Despite these findings, the
30-day mortality rate in women remained significantly greater
after adjustment for clinical and angiographic variables than
that in men. These data support the use of thrombolytic
therapy as an effective means of ventricular salvage regardless
of gender.
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